Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
However, most cancer recurrences happen within the first year of treatment. Long-term ICI therapy can also cause lasting side effects and be expensive. Doctors are therefore interested in finding ways to identify which patients can stop maintenance therapy sooner.
Researchers want to see how well volrustomig works to treat people with inoperable head and neck squamous cell cancer (HNSCC). Inoperable means the cancer cannot be taken out with surgery. The people in this study have HNSCC that has not grown after chemotherapy and radiation given at the same time.
Researchers want to see if ficerafusp alfa plus pembrolizumab is safe and works well against head and neck cancer. They will assess different doses of ficerafusp alfa to find the best one. The people in this study have head and neck squamous cell carcinoma. Their cancers have come back or metastasized (spread) after treatment.
Researchers are evaluating PYX-201 in people with solid tumors that have spread and keep growing after treatment. The people in this study have these cancers:
The purpose of this study is to find the highest dose of the investigational immunotherapy drug REGN7075 that can be given alone and in combination with cemiplimab in people with inoperable or metastatic solid tumors. Patients will either receive REGN7075 alone followed by REGN7075 plus cemiplimab, or only combination treatment with REGN7075 plus cemiplimab. Both drugs are given intravenously (by vein).
The purpose of this study is to find the highest dose of the investigational drug LOXO-435 that can be given safely in people with advanced solid tumors that have come back or continued to grow despite treatment and contain a change in the FGFR3 gene. LOXO-435 targets cells with this abnormality and blocks the activity of FGFR3, a protein that plays a role in cancer growth. Inhibiting this protein could slow or stop the growth of cancer. LOXO-435 is taken orally (by mouth).
Plasmablastic lymphoma is a type of B-cell non-Hodgkin lymphoma (NHL). The purpose of this study is to determine if adding daratumumab to a standard chemotherapy regimen (DA-EPOCH) is a safe way to increase the effectiveness of treatment in people with plasmablastic lymphoma.
Researchers want to find the best dose of INCA033989 to use in people with myelofibrosis (MF) and essential thrombocytopenia (ET). These diseases are called myeloproliferative neoplasms. The people in this study have myeloproliferative neoplasms that came back or keep growing even after treatment. In addition, their cancers have a mutation (change or variant) in the CALR exon-9 gene.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
Researchers want to see how well ivonescimab works as a treatment for endometrial and cervical cancers. The people in this study have endometrial or cervical cancer that keeps growing after treatment.
